DMAC vs LDOS · $157.4M cap vs P/E 16, rev $16.66B
DiaMedica Therapeutics Inc (DMAC) versus Leidos Holdings Inc (LDOS) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
Leidos Holdings Inc (LDOS) is a information technology services company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported LDOS revenue for 2025-01-03 was $16.66B. Net income was $1.25B. Revenue was up 7.9% from 2023-12-29 to 2025-01-03. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
DMAC currently screens at market cap $157.4M. LDOS currently screens at market cap $20.04B and trailing P/E 15.7.
Not investment advice. Open the DMAC and LDOS stock pages for the full models.
Not investment advice.